Success Story: Overcoming RFE to Advance Diagnostic and Therapeutic Research for HIV and COVID-19: EB-2 NIW Approval Secured for a Biomedical Science Researcher from China
Client’s Testimonial:
"Wegreened has been professional, thorough, and meticulous throughout my entire NIW application process. Their team was consistently responsive, answering every question promptly with detailed explanations and supporting evidence. When I received an RFE, they developed a well-tailored response strategy that was both insightful and effective, playing a key role in the successful approval of my petition. My only mild criticism is that there were times when responses took longer than expected. However, given the quality and attention to detail of their work, I felt the extra time was worthwhile.”
On July 5th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for an Internal Medicine Resident Physician in the field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Internal Medicine Resident Physician
Country of Origin: China
State of Residence at the Time of Filing: New York
Approval Notice Date: July 5th, 2026
Processing Time: 1 year, 9 months, 1 day (Premium Processing Requested)
Case Summary:
The client’s work addresses key challenges in understanding cellular markers, signaling pathways, and clinical responses in HIV, COVID-19, cancer, and systemic illnesses. His research focuses on developing improved diagnostic and therapeutic strategies to optimize patient care for complex diseases with major public health impact. At the time of filing, he was conducting biomedical research as an Internal Medicine Resident Physician, applying clinical data analysis and translational methods to advance disease diagnosis and treatment.
Research with National Importance
His work tackles pressing public health concerns in the United States, informing better diagnostic approaches and treatment optimization for HIV, COVID-19, and other systemic illnesses. By linking cellular and molecular insights with patient outcomes, the client’s research supports national health priorities, strengthens U.S. healthcare capabilities, and guides strategies for disease control and prevention.
Academic Contributions and Recognition
At the time of filing, the client’s record included 4 peer-reviewed journal articles (1 first-authored, 1 co-first-authored), 2 conference abstracts (1 first-authored), and 1 preprint, with a total of 73 citations. His research has influenced studies on patient outcomes, disease transmission, and immune signaling mechanisms, providing foundations for subsequent investigations and clinical applications globally.
Expert Endorsements
Experts highlighted the practical impact of the client’s work on public health and biomedical research.
One expert noted:
“By aligning with global health objectives and ethical research standards, [client]’s findings will improve patient outcomes and contribute to the broader goals of health security and innovation in the United States and beyond.”
This endorsement demonstrates the significance of his contributions beyond publication metrics, further reinforcing the national importance of his research.
NIW Approval and Outlook
The I-140 NIW petition was filed on October 4th, 2024, later upgraded to Premium Processing, and approved on July 5th, 2026. The petition successfully overcame an RFE issued on February 13th, 2026, which requested clarification on the national significance and impact of his research. The approval recognized the importance of his work in optimizing diagnostics, understanding disease mechanisms, and developing therapeutic strategies.
This outcome supports the client’s continued efforts to advance biomedical research, improve patient care, and contribute to U.S. public health innovation. We congratulate him on this approval and wish him continued success in translational biomedical research.